Belviq Lawsuits For Pancreatic Cancer, Colon Cancer, Rectal Cancer, Lung Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
In February 2020 there was a Belviq recall due to cancer cases observed in a Belviq safety clinical trial. The Belviq FDA Drug Safety Communication announcing this Belviq recall, “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”, noted that excess cases of pancreatic cancer, colon cancer, rectal cancer, and lung cancer were observed. This Belviq recall has resulted in Belviq lawsuits being filed against the responsible pharmaceutical company, Eisai Inc.
The Data Summary section of the Belviq FDA Drug Safety Communication set forth these findings from the Belviq safety clinical trial:
Imbalances in specific cancers including pancreatic, colorectal, and lung contributed to the observed overall imbalance in cancer cases. There was no apparent difference in the incidence of cancer over the initial months of treatment, but the imbalance increased with longer duration on [Belviq (lorcaserin)].
According to the FDA, these are some of the specific types of cancer associated with Belviq:
- Pancreatic Cancer
- Colorectal Cancer
- Colon Cancer
- Rectal Cancer
- Lung Cancer
Our law firm is investigating possible Belviq lawsuits where patients have been diagnosed with cancer, including but not limited to the types listed above.
We encourage you to submit a Belviq Lawsuits Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Belviq
In this FDA staff article, “Cancer risk associated with lorcaserin — The FDA’s review of the CAMELLIA-TIMI 61 trial”, which was published by the New England Journal of Medicine (NEJM), the early 2020 FDA Belviq recall decision was explained. Essentially, this FDA action after a careful analysis of Belviq safety data that revealed excess risks of cancers and deaths.
To read more of this article, click below:
The cancers risks aspect of this Belviq safety data review that led to the FDA Belviq recall decision was summarized in a September 9, 2020, Medpage Today news report, “A Closer Look at FDA Decision to Pull Lorcaserin”:
Colorectal cancer occurred more frequently in the [Belviq (lorcaserin)] group, with 26 versus 14 with placebo, as did pancreatic cancer (16 vs 2, respectively), lung cancer (40 vs 25), leukemia (12 vs 6), hepatobiliary cancers (10 vs 4), and others.
The following excerpt from this recent FDA NEJM Belviq article explains the Belviq safety data review which led to the FDA Belviq recall decision:
The cancer-related safety signal from nonclinical studies supports the plausibility of an excess cancer risk from [Belviq (lorcaserin)], and the consistency of cancer findings in CAMELLIA-TIMI 61 and the robustness of sensitivity analyses further support a causative effect…. Although we cannot exclude the possibility that the observed imbalances are due to chance, conducting another trial to confirm or refute the signal isn’t feasible.
Our law firm is investigating possible Belviq lawsuits where patients have been diagnosed with cancer, including but not limited to the types identified in the Medpage Today article about the FDA Belviq safety data review.[Read article in full at original source]
Earlier articles about Belviq by attorney Tom Lamb on the Side Effects Blog:
- After Drug Recall Belviq Lawsuits Alleging Failure To Warn About Cancer
- Belviq Recall Due To Certain Cancers: Pancreatic, Colon, Rectal, And Lung
- Weight-Loss Medicine Belviq Increased Risk Of Cancers Says FDA Drug Safety Communication